Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Lipid Screening in Children with NAFLD

J Pediatr; ePub 2018 Apr 13; Harlow, et al

More than 50% of children with nonalcoholic fatty liver disease (NAFLD) met intervention thresholds for dyslipidemia, warranting lipid screening in this population group. This according to a multicenter, longitudinal cohort study that included 585 children (mean age 12.8 years) with NAFLD. Fasting lipid profiles were obtained at diagnosis. After 1 year, lipid profiles were repeated and interpreted according to National Heart, Ling, and Blood Institute Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction. Main outcomes were meeting criteria for clinically actionable dyslipidemia at baseline, and either achieving lipid goal at follow-up or meeting criteria for ongoing intervention. Researchers found:

  • The prevalence of children warranting intervention for low-density lipoprotein cholesterol (LDL-C) at baseline was 14%.
  • After 1 year of recommended dietary changes, 51% achieved goal LDL-C, 27% qualified for enhanced dietary and lifestyle modifications, and 22% met criteria for pharmacologic intervention.
  • Elevated triglycerides were more prevalent, with 51% meeting criteria for intervention.

Citation:

Harlow KE, Africa JA, Wells A, et al. Clinically actionable hypercholesterolemia and hypertriglyceridemia in children with nonalcoholic fatty liver disease. [Published online ahead of print April 13, 2018]. J Pediatr. doi:10.1016/j.jpeds.2018.02.038.

This Week's Must Reads

Improving CV Health in Women Through Provider Collaboration, Circulation; ePub 2018 May 10; Brown, et al

Burden of AF With Risk of Stroke in Paroxysmal AF, JAMA Cardiol; ePub 2018 May 16; Go, et al

OSA & Risk of Hospitalization in Patients with HFpEF, Am J Cardiol; ePub 2018 May 11; Abdullah, et al

Air Pollution Exposure in Pregnancy & Risk of High BP, Hypertension; ePub 2018 May 14; Zhang, et al

Total & CV Mortality After LDL-C Lowering, JAMA; 2018 Apr 17; Navarese, et al

Must Reads in Hypercholesterolemia

Total & CV Mortality After LDL-C Lowering, JAMA; 2018 Apr 17; Navarese, et al

PCSK9 Inhibitors for Tx of Hypercholesterolemia, Ann Pharmacother; ePub 2018 Apr 1; Patel, et al

High-Intensity Statin Use and LDL-C Control, J Clin Lipidol; ePub 2018 Apr 26; Lamprecht Jr, et al

Improving Adherence with ASCVD Interventions, Clin Cardiol; ePub 2018 Apr 17; Fentanes, et al

Lipid Screening in Children with NAFLD, J Pediatr; ePub 2018 Apr 13; Harlow, et al